The Short Answer — And Why It Varies
For a catalog-based OEM program — your branding applied to an existing manufacturer’s instrument range — a well-managed launch takes 12 to 16 weeks from signed commercial agreement to first delivered production. Add the pre-agreement phase (manufacturer evaluation, brand development, specification brief), and the total timeline from decision to delivery runs 16 to 20 weeks.
For a custom-specification program — new instrument designs, modified geometries, proprietary components — add another 12 to 18 weeks on top of that. Full custom programs realistically take 28 to 40 weeks from program initiation to first production delivery.
These numbers surprise most distributors who have been told by eager manufacturer sales reps that they can be up and running in eight weeks. They cannot — not with a properly managed sample approval process, a legitimate regulatory review, and packaging that will actually pass a barcode scan at hospital receiving. Eight-week promises produce twelve-week launches with quality problems discovered after the first customer order.
This article breaks down every phase of the launch process with honest week counts, identifies the seven most common reasons timelines slip, and shows what can be run in parallel to compress the overall schedule without cutting corners on the steps that actually matter
Track A vs Track B: Two Programs, Two Timelines
Before walking through the phase detail, it helps to understand the two fundamental program tracks — because the timeline difference between them is not marginal.
Factor | Track A: Catalog OEM | Track B: Custom Specification |
Base product | Manufacturer’s catalog item | New or modified design |
Total timeline | 12–16 weeks (well-managed) | 28–40 weeks |
First-order MOQ | 200–800 units per SKU | 1,000–5,000 units per SKU |
Tooling investment | Minimal (engraving die only) | Moderate–High (custom components) |
Brand setup cost | $3,500–$7,000 (packaging + engraving) | $15,000–$60,000+ (design + tooling) |
Regulatory complexity | Standard — manufacturer retains docs | Higher — may require new IFU, testing |
Quality risk (first run) | Low — proven base instrument | Moderate — new spec requires validation |
Commercial advantage | Speed to market, lower investment | Full differentiation, proprietary design |
Best for | First-time private label programs | Established programs expanding into custom |
The rest of this guide focuses primarily on Track A — the catalog OEM program — because it is the appropriate starting point for the vast majority of distributors launching a private-label line for the first time. Track B considerations are covered in the final section.
The Visual Timeline — 20-Week Catalog OEM Program
The Gantt chart below maps the overlapping phases of a well-managed catalog OEM private-label launch across a 20-week window. Color coding reflects the responsible work stream: blue for manufacturer/production activities, green for brand and commercial activities, amber for regulatory and approval activities, and orange for packaging production.
|
Phase / Activity |
W1 |
W2 |
W3 |
W4 |
W5 |
W6 |
W7 |
W8 |
W9 |
W10 |
W11 |
W12 |
W13 |
W14 |
W15 |
W16 |
W17 |
W18 |
W19 |
W20 |
|
TRACK A: |
||||||||||||||||||||
|
Category |
■ |
■ |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Manufacturer |
|
■ |
■ |
■ |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Brand Identity |
|
■ |
■ |
■ |
■ |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Trademark |
|
|
■ |
■ |
■ |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Commercial |
|
|
|
|
■ |
■ |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Packaging |
|
|
|
|
|
■ |
■ |
■ |
■ |
■ |
|
|
|
|
|
|
|
|
|
|
|
Sample |
|
|
|
|
|
■ |
■ |
■ |
|
|
|
|
|
|
|
|
|
|
|
|
|
Sample |
|
|
|
|
|
|
|
■ |
■ |
■ |
|
|
|
|
|
|
|
|
|
|
|
Regulatory |
|
|
|
|
|
|
|
■ |
■ |
■ |
|
|
|
|
|
|
|
|
|
|
|
Production |
|
|
|
|
|
|
|
|
|
■ |
■ |
■ |
■ |
■ |
■ |
|
|
|
|
|
|
Market |
|
|
|
|
|
|
|
|
|
|
|
|
■ |
■ |
■ |
■ |
|
|
|
|
|
First |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
■ |
■ |
|
|
|
|
|
TRACK B: |
||||||||||||||||||||
|
Reading the chart Filled cells indicate weeks when that activity is actively in progress. Overlapping rows show where parallel work streams run simultaneously — the key to compressing the overall timeline. Activities that cannot overlap (sample approval must follow sample production; production order cannot be placed before agreement is signed) are shown in sequence. |
Phase-by-Phase Breakdown — With Real Week Counts
|
Phase Timeline: Weeks |
|
Key tasks: Identify target SKUs from existing sales data. Define Timeline |
|
Phase Timeline: |
|
Key tasks: Apply qualification criteria: FDA registration, ISO 13485 Timeline |
|
Phase Timeline: |
|
Key tasks: Develop brand name and logo — can be done in parallel with Timeline |
|
Phase Timeline: |
|
Key tasks: Negotiate and finalize: unit pricing by volume tier, MOQ Timeline |
|
Phase 5: Packaging Design and Pre-Press Production Timeline: Weeks 6–10 | Owner: Buyer + Packaging Designer + Print Supplier |
|
Key tasks: Commission packaging dieline and artwork from a medical packaging designer. Include all required labeling elements: product name, lot number field, manufacturer information, UDI/GTIN barcode, IFU reference, CE/FDA marking as applicable. Submit for pre-press proof. Approve PDF proof. Order physical press proof. Approve and release to print production. Timeline risk: Very high. Packaging is the most common single cause of launch delay. Errors in barcode structure, missing regulatory text, or color accuracy issues discovered at the press proof stage require reprints that add 2–4 weeks. Use a packaging designer with medical device labeling experience — not a general graphic designer. |
|
Phase 6: Sample Production and Formal Approval Timeline: Weeks 6–10 (parallel with Phase 5) | Owner: Manufacturer + Buyer QA |
|
Key tasks: Manufacturer produces pre-production samples with engraving/branding applied. Buyer evaluates against defined acceptance criteria: dimensional tolerances, surface finish, cutting edge performance, ratchet/jaw function. Packaging samples evaluated separately. Formal sample approval documented in writing with retained physical samples. Timeline risk: Moderate to high. Approval cycles with multiple internal stakeholders and no defined decision timeline regularly extend to three or four weeks. Designate a single approval authority and set a two-week hard deadline from sample receipt. |
|
Phase 7: Regulatory Review Timeline: Weeks 8–10 (parallel with Phases 5 and 6) | Owner: Buyer Regulatory / Legal |
|
Key tasks: Confirm manufacturer FDA registration is current. Obtain ISO 13485 certificate with expiry date. Review IFU documentation for each instrument SKU. For single-use products: confirm sterile barrier validation documentation. For labeled products: confirm UDI compliance and labeling accuracy against 21 CFR Part 801 requirements. Timeline risk: Low if planned. Regulatory review that starts in parallel with sample approval adds zero time to the overall schedule. Regulatory review that begins after sample approval — the most common sequencing error — adds two to four weeks. |
|
Phase 8: Production Order Placement and Manufacturing Lead Time Timeline: Weeks 10–15 | Owner: Buyer + Manufacturer |
|
Key tasks: Following signed agreement, approved samples, completed regulatory review, and confirmed packaging: place the production order. Standard manufacturing lead time for catalog OEM instruments: 4–6 weeks from order placement to goods ready to ship. Air freight transit (manufacturer to US): 5–8 days. Sea freight: 3–5 weeks (significantly cheaper; plan accordingly). Timeline risk: Low if previous phases are complete. Production lead time is fixed once the order is placed. The risk here is placing the production order before packaging is confirmed — instruments arrive ready but packaging is delayed, and the launch stalls at the final step. |
|
Phase 9: Market Launch Preparation Timeline: Weeks 13–16 (parallel with production) | Owner: Sales and Marketing |
|
Key tasks: Prepare customer communication about the new branded line. Develop sales materials and product sheets. Brief field sales team on product specifications, pricing, and the private-label brand story. Identify pilot accounts for early launch and arrange instrument samples for sterile processing evaluation where required. Timeline risk: Low for the timeline, high for commercial success. Launch preparation that happens after delivery rather than during production means the first customer conversations happen weeks after instruments are available — leaving inventory sitting in a warehouse while sales ramps. |
|
Phase 10: First Delivery, Incoming QC, and Post-Launch Review Timeline: Weeks 15–16 and ongoing | Owner: Buyer QA + Operations |
|
Key tasks: Receive first production. Conduct incoming inspection against approved samples: instrument quality, packaging accuracy, barcode scan confirmation, labeling completeness. Document inspection results. Release to inventory. Conduct a post-launch review at 30 and 90 days: customer feedback, any quality complaints, reorder timing, and SKU performance versus projections. Timeline risk: Low for timeline; critical for program health. Distributors who skip incoming inspection on the first production run discover deviations from approved samples at the customer complaint stage — which is a much more expensive problem than catching them at the receiving dock. |
The Seven Most Common Timeline Killers
Almost every private-label launch that runs over schedule traces back to one of the following seven causes. Understanding them before the program starts is the most effective form of timeline management.
Delay Cause | Typical Time | How It |
Incomplete | +2–4 weeks | Manufacturer |
Brand | +2–3 weeks | Packaging |
Skipped or | +4–8 weeks | Discovering a |
Slow sample | +2–6 weeks | Multiple |
Regulatory | +2–4 weeks | For single-use |
Packaging | +3–5 weeks | Barcode |
MOQ | +1–3 weeks | MOQ disputes |
What You Can Do in Parallel to Compress the Timeline
The Gantt chart above shows the overlapping work streams in a well-managed program. The following parallel activities are the highest-leverage compression levers available to a distributor — each one reduces the overall timeline without compromising quality:
- Start brand development in Week 2, not after the commercial agreement is signed. Brand identity work has no dependency on the manufacturer agreement — it runs independently and should always start in parallel with manufacturer evaluation.
- Begin packaging design as soon as brand identity is locked — typically Week 5 or 6. Do not wait for sample approval to start the packaging dieline. The packaging timeline (design, proof, print production) runs 4–6 weeks on its own. Starting it after sample approval adds those weeks to the back of the program.
- Run regulatory review in parallel with sample production, not sequentially after sample approval. Regulatory documentation from the manufacturer (FDA registration, ISO 13485 certificate, IFU drafts) can be reviewed while samples are being produced.
- Begin market launch preparation (sales briefing, customer communication, product sheets) during the production lead time window — Weeks 10 to 15. This costs no additional calendar time and means your sales team is ready on Day 1 of delivery.
- Place the production order as soon as the commercial agreement is signed and samples are in production — do not wait for sample approval to have the production conversation. You can place a conditional production order that converts to a firm order upon sample approval.
Maximum compression possible A distributor |
Custom Specification Programs — Why They Take Longer
Custom specification programs involve instrument designs that do not exist in any manufacturer’s catalog. This might mean a new jaw configuration, a modified shaft length outside standard ranges, a proprietary handle design, or a material specification that differs from the manufacturer’s standard alloy.
The additional time in a custom program is concentrated in three areas that do not exist in catalog OEM programs:
- Design and engineering review — the manufacturer’s production engineering team must review the custom specification for manufacturability, set tolerances, and identify any tooling requirements. This process typically takes two to four weeks and may involve multiple revision cycles before the specification is production-ready.
- Tooling fabrication — custom components (dies, jigs, specialized fixtures) must be fabricated before samples can be produced. Tooling lead times range from three to eight weeks depending on complexity. This cannot be compressed and cannot run in parallel with anything that depends on the tooling.
- Extended sample approval cycles — custom instruments have no approved precedent to compare against. The first sample run almost always requires modification, producing a second sample cycle that adds four to six weeks. Budget for two sample rounds, not one.
For distributors considering a custom specification program: the investment is justified when your specification creates genuine clinical differentiation — a feature, geometry, or performance characteristic that catalog instruments cannot replicate. If the custom element is primarily cosmetic (a different handle color, a slightly different length that falls within catalog range), a catalog OEM program achieves the commercial goal at a fraction of the investment and timeline.